Potential genetic robustness of *Prnp* and *Sprn* double knockout mouse embryos towards ShRNA-lentiviral inoculation

Andrea Rau^{1,2}, Bruno Passet¹, Johan Castille¹, Alexandre Asset¹, Jérôme Lecardonnel¹, Marco Moroldo¹, Florence Jaffrézic¹, Denis Laloë¹, Katayoun Moazami-Goudarzi¹, Jean-Luc Vilotte¹

¹ Université Paris-Saclay, INRAE, AgroParisTech, GABI, 78350 Jouy-en-Josas, France.

² BioEcoAgro Joint Research Unit, INRAE, Université de Liège, Université de Lille, Université de Picardie Jules Verne, 80203 Peronne, France.

*Corresponding author email: andrea.rau@inrae.fr

Author E-mails :

andrea.rau@inrae.fr; bruno.passet@inrae.fr; johan.castille@inrae.fr; a.asset@orange.fr;
jerome.lecardonnel@inrae.fr; marco.moroldo@inrae.fr; florence.jaffrezic@inrae.fr;
denis.laloe@inrae.fr; katayoun.moazami-goudarzi@inrae.fr; jean-luc.vilotte@inrae.fr

Highlights

- *Sprn-ShRNA* lentivirus vector inoculation in *Prnp* knockout one-cell mouse embryos results in the induction of an apoptosis pathway at E6.5, alongside interferon and to a lesser extent inflammatory responses.
- *Sprn- or Prnp-ShRNA* lentivirus vector inoculations in *Prnp/Sprn* knockout one-cell mouse embryos induce lower interferon responses and no apoptotic pathway at E6.5.
- Although wild type and *Prnp/Sprn* knockout E6.5 mouse embryos are transcriptomically similar, some differences might explain this apparent resilience of the double knockout genotype.

Abstract

Shadoo, encoded by *Sprn*, and PrP, encoded by *Prnp*, are related proteins whose biological functions are still incompletely understood. Although previous knockdown experiments have suggested the necessity of Shadoo in the absence of PrP during early mouse embryogenesis, little impact of the double-knockout of these two loci was reported. To further investigate this apparent discrepancy, we compared the transcriptome of WT, *Prnp*^{0/0} and *Prnp*^{0/0}, *Sprn*^{0/0} E6.5 mouse embryos following inoculation by *Sprn*-ShRNA or *Prnp*-ShRNA lentiviral vectors at the one-cell stage. Our results highlighted a significant induction of an apoptotic pathway in *Prnp*^{0/0} E6.5 mouse embryos inoculated with *Sprn*-ShRNA vectors alongside interferon and to a lesser extent inflammatory responses, confirming previous reported experiments. On the contrary, ShRNA vector inoculation in *Prnp*^{0/0}, *Sprn*^{0/0} embryos did not induce apoptosis and resulted in lower interferon responses. Finally, comparisons of the transcriptome of WT and *Prnp*^{0/0}, *Sprn*^{0/0} embryos revealed only slight differences, which may in part explain the genetic robustness observed in the latter genotype.

Keywords

Mouse, Prion, Shadoo, lentivirus, ShRNA, robustness

1. Introduction

PrP, the prion protein encoded by *Prnp* whose abnormally folded isoform is the key component of infectious prion particles responsible for Transmissible Spongiform Encephalopathies, and Shadoo, encoded by *Sprn*, are evolutionarily related [1]. Their biological functions remain incompletely understood, and their individual genetic invalidations result in no overt phenotypes beyond resistance to prion infection for *Prnp*-knockout mice. The early embryonic lethality, already noticeable at E7.5 with a developmental failure of the trophoctoderm-derived compartment, of *Prnp*-knockout, *Sprn*-knockdown embryos initially suggested a biological redundancy of these two proteins [2]. However, the development of *Prnp* and *Sprn* double knockout mice in various genetic backgrounds [3,4] did not confirm this hypothesis. These apparently contradictory observations could result from a genetic compensation in invalidated animals [5] or from an increased robustness [6].

In the present report, we comparatively assessed, at the transcriptomic level, the impact of *Prnp* and *Sprn* knockout in E6.5 mouse embryos and its consequences following inoculation with *ShRNA*-lentiviral vectors at the one cell stage.

2. Materials and Methods

2.1 Ethics statements. Animal experiments were carried out in accordance with the EU Directive 2010/63/EU. Production, breeding and inoculations at the one cell stage with *ShRNA*-lentiviral vectors of the various transgenic lines were approved by the Ethics Committee of Jouy-en-Josas (Comethea, Permit number 02532.01), and followed the safety recommendations of the French “Haut Conseil des Biotechnologies” (HCB, Permit numbers 6460 and 5468).

2.2 Transgenic lines and lentiviral inoculations. Transgenic *Prnp* and *Sprn* FVB/N knockout mouse lines were already described [2,4,7]. Wild type (WT) FVB/N mice were purchased from Janvier (https://www.janvier-labs.com/fiche_produit/souris_fvb). *ShhRNA* lentiviral vector solutions were purchased from Sigma with infectious titers over 10⁹ infectious units/ml (LS1: TRCN0000179960 and LS2: TRCN0000184740 against *Sprn* transcripts, LP1: TRCN0000319687 and LP2: TRCN 0000273801

against *Prnp* transcripts). Intra-perivitellin space injections and transplantation into pseudo-pregnant recipient mice were performed as previously described [2]. Around 50 one-cell stage embryos were injected for each genotype and lentiviral solution combination (Figure 1A).

Figure 1: Schematic representation of study design and analysis. (A) Transgenic lines and lentiviral inoculations; (B) embryo collection; (C) transcriptomic analyses; (D) hallmark gene set analysis; and (E) differential expression analysis.

2.3 Embryo collection and transcriptomic analyses. Embryos were collected at E6.5 (Figure 1B). Total RNA was isolated from pools of 6-14 E6.5 embryos, deriving from 3 to 5 females. RNA extractions and integrity analysis were performed as previously described [2]. Three to four independent pools were produced for each experimental group (i.e., genotype and lentiviral solution combination) and analysed using Agilent SurePrint G3 gene expression V2 8x60K mouse microarrays (AMADID: 074809, Figure 1C). All steps were performed by the @BRIDGE facility (INRAE Jouy-en-Josas, France, <http://abridge.inra.fr/>), as described previously [8].

All analyses were performed with R version 4.0.0. Median pixel intensity and local background intensity were read and pre-processed from the raw Agilent files using the R/Bioconductor package *limma* (version 3.44.1, [9,10]). Probe intensities were quantile-normalized and log₂-transformed [11]. Using the “glsWellAboveBackground” flag, non-control probes were called as present if they were above background in at least 3 samples. After averaging intensities for remaining probes with identical target sequences, a single representative probe was chosen for each gene according to the maximum observed variance across samples (Figure 1C). Raw microarray data files and all analysis scripts needed

to pre-process the data and reproduce the analyses described in this work are openly available on the Data INRAE portal at <https://data.inrae.fr/privateurl.xhtml?token=e7b8885d-9cef-43c9-ae98-06259ee84d44>.

2.4 Hallmark gene set analyses. To evaluate the potential role played by specific ensembles of gene sets, hallmark gene sets from the Molecular Signatures Database (MSigDB, [13,14]) were obtained for *Mus musculus* using the *msigdb* package (version 7.2.1). Among the 50 available gene sets, we focused our attention on a subset of 14 hallmark gene sets related to PrP recognized physiological functions (see below). Comparisons of interest for the hallmark gene set analysis were defined for four different experimental groups as compared to WT mice: (1) *Prnp*^{0/0}, *Sprn*^{0/0}; (2) *Prnp*^{0/0}, *Sprn*^{0/0}, *Sprn*^{KD}; (3) *Prnp*^{0/0}, *Sprn*^{0/0}, *Prnp*^{KD}; and (4) *Prnp*^{0/0}, *Sprn*^{KD}. To minimize possible off-target effects, contrasts for comparisons with groups (2)-(4) were constructed by averaging over the two lentiviruses for each gene knockdown. Using the *fry* self-contained rotation gene set test from *limma* [15], we sought to identify whether genes in each selected hallmark gene set were globally differentially expressed for a given comparison (Figure 1D). *P*-values were calculated corresponding to tests for gene sets exhibiting significant over-expression (“Up”) and under-expression (“Down”), as well as differential expression regardless of direction (“Mixed”). Raw *P*-values were corrected for multiple testing using the Benjamini-Hochberg approach to control the false discovery rate (FDR, [12]), and gene sets were identified as significantly globally differentially expressed if their adjusted *P*-value < 0.05.

2.5 Differential expression analysis. For the differential analysis (Figure 1E), a linear model with group-means parameterization (i.e., no intercept and a separate coefficient for each group) was fit for each gene. Using *limma*, an empirical Bayes approach was used to moderate the standard errors of the estimated log-fold changes. Contrasts were defined to identify differentially expressed genes for each comparison of interest; we focused in particular on the comparison of *Prnp*^{0/0}, *Sprn*^{0/0} and WT E6.5 embryos. As before, *P*-values were corrected for multiple testing using the Benjamini-Hochberg

approach to control the false discovery rate [13], and genes were identified as significantly differentially expressed if their adjusted *P*-value < 0.05 and absolute log fold change > 1.

3. Results and discussion

3.1 Knockdown of *Sprn* in mouse *Prnp*^{0/0} embryos induces apoptosis alongside interferon responses at E6.5

Although *Prnp*^{0/0}, *Sprn*^{0/0} mice are viable [3,4], the knockdown of *Sprn* in *Prnp*^{0/0} mouse embryos was reported to induce embryonic lethality highlighted by a developmental failure of the trophectoderm-derived compartment noticeable at E7.5 [2]. We reinvestigated this latter observation by transcriptomic analysis of such embryos at E6.5, focusing on a subset of MSigDB including 14 hallmark gene sets related to PrP recognized physiological functions ([1,16-18], Table 1). Three of those hallmark gene sets were significantly altered in *Sprn*-knockdown, *Prnp*^{0/0} E6.5 embryos compared to their WT counterparts (adjusted *P*-value < 0.05): interferon- α and γ responses and apoptosis, while inflammatory response was significant with an adjusted *P*-value < 0.10 (Table 1). These data confirm the above-mentioned previous report, emphasizing that embryonic lethality could be diagnosed at earlier developmental stages. Because two different ShRNA were used, targeting different regions of the *Sprn* transcript, it is unlikely that apoptosis results from an off-target effect. We next wondered if this apoptotic induction, alongside inflammatory and interferon responses, could result from the association of a lentiviral ShRNA-expressing vector inoculation [19] with a *Prnp*-knockout induced interferon-primed state [20] in the absence/reduction of *Sprn* expression, as it was previously shown that this latter is required to induce apoptosis [2].

[Table 1]

3.2 *Prnp* or *Sprn* knockdown in mouse *Prnp*^{0/0}, *Sprn*^{0/0} embryos induces reduced interferon responses and no apoptosis at E6.5

We similarly investigated the transcriptomic outcomes at E6.5 of *Sprn*- or *Prnp*-knockdown in *Prnp*^{0/0}, *Sprn*^{0/0} mouse embryos. The knockdown of *Sprn* or *Prnp* were performed on a knockout genotype for both these genes to highlight only those pathways associated with lentiviral ShRNA vector infections on this specific genetic background. Two different ShRNA were again used for each targeted gene to reduce the likelihood of observing an off-target-induced biological disturbance. Compared to WT E6.5 embryos, only two hallmark gene sets were altered consistently and significantly: interferon- α and $-\gamma$ responses (Table 1). However, compared to the previous analysis, the statistical significance of these gene sets was unexpectedly reduced by 10-fold. Furthermore, no apoptosis induction was detected (Table 1).

These results could suggest that the expression or the knockout of *Sprn* is required to avoid lentiviral ShRNA vector induction of a strong interferon response associated with apoptosis in *Prnp*^{0/0} mouse embryos, while its knockdown exacerbates these pathways. A potential explanation for these apparent contradictory observations is that the knockout of the two genes induces a genetic adaptation that in turn helps control the lentiviral-induced responses. Such an adaptation might not take place with the *Sprn*-knockdown or to an insufficient level.

3.3 Transcriptomes of WT and *Prnp*^{0/0}, *Sprn*^{0/0} E6.5 embryos are highly similar with only few differentially expressed genes

To assess this hypothesis, we next compared the transcriptome of E6.5 WT and *Prnp*^{0/0}, *Sprn*^{0/0} mouse embryos. Only 11 genes were found to be differentially expressed between these two genotypes with an adjusted P-value < 0.05 and absolute log fold change > 1 (Table 2). All 11 of these genes were similarly found to be significantly differentially expressed in the same direction in *Sprn*-knockdown, *Prnp*^{0/0} compared to WT E6.5 mouse embryos, albeit with weaker log fold changes for the majority. As already discussed, the *Prnp* and *Sprn* gene invalidations did not induce alteration of their transcript expression levels and their absence in this list was thus expected [4,7]. Most of the differentially expressed genes were reported to be transcribed in the embryo ectoderm and mesenchyme, and only

few in the endoderm or in the extraembryonic component (<http://www.informatics.jax.org/expression.shtml>, Table 2). Since adult expression of both *Prnp* and *Sprn* genes is more abundant in the nervous system, and since PrP involvement in muscle and bone development/regeneration has been previously reported, deregulation of these genes in the ectoderm and in the mesenchyme might be relevant observations. However, in *Sprn*-knockdown, *Prnp*^{0/0} embryos, a developmental failure of the trophectoderm-derived compartment was reported [2], rather suggesting a major role of the extraembryonic component in the appearance of this lethality.

[Table 2]

Only 3 out of the 11 genes are expressed in the extraembryonic component: *Spint1*, *Cds2* and *Ada* (Table 2). *Spint1* was recently reported to be a biomarker of placental insufficiency [21]. Low circulating levels of *Spint1* are associated with placental failure whereas here, at E6.5, this expression is higher in *Prnp*^{0/0}, *Sprn*^{0/0} embryos compared to their WT counterparts. Whether *Spint1* overexpression can favor placental development remains to be demonstrated. *Cds2* is a widely expressed gene indirectly involved in the positive control of angiogenesis [22]. Its overexpression in *Prnp*^{0/0}, *Sprn*^{0/0} embryos could suggest a sustained angiogenesis of the placenta, but in the absence of associated deregulation of co-factors, such as vascular endothelial growth factors, the interpretation of this observation remains fragile. Nevertheless, the differential expression of the two above-mentioned genes appears to favor placental development and to contribute to the survival of the *Prnp*^{0/0}, *Sprn*^{0/0} mouse embryos. However, their potential implication in the control of the interferon response remains elusive.

3.4 *Ada* downregulation in *Prnp*^{0/0}, *Sprn*^{0/0} E6.5 embryos could explain the apparent genotype robustness

The third gene, transcribed in the extraembryonic component and strongly differentially expressed (Log fold change -2.1, Table 2, Figure 2) is *Ada*. Disruption of the *Ada* gene in mice induces perinatal lethality [23], a phenotype rescued by tissue-specific placental expression of this gene [24]. Its crucial

role in the trophoblast-derived compartment was also indirectly emphasized through the knockout of the AP-2 γ transcription factor-encoding gene that resulted in an early embryonic lethal phenotype, similar to that observed for *Sprn*-knockdown, in *Prnp*^{0/0} embryos [2,25], associated with a lack of *Ada* gene expression in the extraembryonic cells [26]. However, in *Prnp*^{0/0}, *Sprn*^{0/0} mouse embryos, only a downregulation of the *Ada* gene expression is observed, thus likely avoiding the occurrence of these drastic phenotypes. It should be mentioned that *Ada*^{0/+} mouse embryos were similarly not reported to be affected [23].

Figure 2: Normalized expression of *Ada* in WT; *Prnp*^{0/0}, *Sprn*^{0/0}; and *Prnp*^{0/0}, *Sprn*^{KD} mice represented as dot plots for individual samples (grey points) with means (black points) and standard deviations (bars) for each experimental group.

Interestingly, *Ada* congenital defect induces a severe combined immunodeficiency syndrome [25]. Expression levels of this enzyme correlate with the production levels of interferons and proinflammatory factors, and modulation of *Ada* activity was even proposed as a potential therapeutic target [26-29]. High interferon responses can induce side effects among which some, such as autoimmune reactions, can be detrimental. The control of the interferon response is thus crucial, and as already mentioned, altered in the absence of members of the prion protein family [16]. The downregulation of the *Ada* gene expression observed in *Prnp*^{0/0}, *Sprn*^{0/0} mouse embryos might help to

control the interferon and inflammatory responses induced by lentiviral ShRNA-encoding vector infections to a level compatible with their survival. This genetic adaptation is only partially induced in *Sprn*-knockdown, *Prnp*^{0/0} embryos, resulting in a high rate of embryonic lethality [2].

3.5 Conclusion

Overall, our results suggest a genetic adaptation of *Prnp*^{0/0}, *Sprn*^{0/0} mouse embryos, both to sustain placental physiology that is affected in the absence of PrP [29] or Shadoo [7] and to refrain the upregulation of induced interferon responses following environmental stresses. This genetic adaptation might involve the downregulation of *Ada* and its-related pathways, this protein being involved in immunomodulation and ectoplacental development. Although this hypothesis remains to be further supported by direct experiments, it offers an explanation for the discrepancy observed between knockdown and knockout in previously reported data [2,3] and adds to the list of knockout genotypes that have acquired genetic adaptation.

Funding

This work was supported by an INRAE Animal Genetics department project grant (grant AAP.GA.2015, COSI-Net).

References

- [1] T. Onodera, T. Nishimura, K. Sugiura et al. Function of Prion Protein and the Family Member, Shadoo. *Curr Issues Mol Biol*. 2020;36:67-88. doi: 10.21775/cimb.036.067.
- [2] B. Passet, R. Young, S. Makhzami et al. Prion protein and Shadoo are involved in overlapping embryonic pathways and trophoblastic development. *PLoS One*. 2012;7(7): e41959. doi: 10.1371/journal.pone.0041959.
- [3] N. Daude, S. Wohlgemuth, R. Brown et al. Knockout of the prion protein (PrP)-like *Sprn* gene does not produce embryonic lethality in combination with PrP(C)-deficiency *Proc Natl Acad Sci U S A*. 2012 Jun 5;109(23):9035-40. doi: 10.1073/pnas.1202130109.
- [4] J. Castille, B. Passet, S. Makhzami et al. Co-invalidation of *Prnp* and *Sprn* in FVB/N mice affects reproductive performances and highlight complex biological relationship between PrP and Shadoo. *Biochem Biophys Res Commun*. 2021 Apr 30;551:1-6. doi: 10.1016/j.bbrc.2021.03.013.
- [5] A. Rossi, Z. Kontarakis, C. Gerri et al. Genetic compensation induced by deleterious mutations but not gene knockdowns. *Nature*. 2015 Aug 13;524(7564):230-3. doi: 10.1038/nature14580.

- [6] G. Schlieper, J.H. Kim, A. Molojavyi et al. Adaptation of the myoglobin knockout mouse to hypoxic stress. *Am J Physiol Regul Integr Comp Physiol*. 2004 Apr;286(4):R786-92. doi: 10.1152/ajpregu.00043.2003.
- [7] B. Passet, J. Castille, S. Makhzami et al. The Prion-like protein Shadoo is involved in mouse embryonic and mammary development and differentiation. *Sci Rep*. 2020 Apr 21;10(1):6765. doi: 10.1038/s41598-020-63805-y.
- [8] N. Mach, Y. Ramayo-Caldas, A. Clark A et al. Understanding the response to endurance exercise using a systems biology approach: combining blood metabolomics, transcriptomics and miRNomics in horses. *BMC Genomics*. 2017 Feb 17;18(1):187. doi: 10.1186/s12864-017-3571-3.
- [9] ME. Ritchie, B. Phipson, D. Wu et al. *limma* powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Research* 2015, 43 (7): e47, doi : 10.1093/nar/gkv007.
- [10] B. Phipson, S. Lee, IJ. Majewski et al. Robust hyperparameter estimation protects against hypervariable genes and improves power to detect differential expression *Ann. Appl. Stat* 2016. 10(2): 946-963. doi: 10.1214/16-AOAS920
- [11] ME. Ritchie, J. Silver, A. Oshlack et al. A comparison of background correction methods for two-colour microarrays. *Bioinformatics* 2007, 23 (20), 2700–2707, doi : 10.1093/bioinformatics/btm412
- [12] Y. Benjamini, J. Hochberg. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society: Series B*. 1995, 57(1):289–300.
- [13] A. Subramanian, P. Tamayo, VK. Mootha et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A* 2005, 102 (43) : 15545-15550. doi : 10.1073/pnas.0506580102
- [14] A. Liberzon, C. Birger, H. Thorvaldsdóttir et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. *Cell Syst*. 2015. 1(6): 417–425. doi: 10.1016/j.cels.2015.12.004.
- [15] D. Wu, E. Lim, F. Vaillant et al. ROAST: rotation gene set tests for complex microarray experiments. *Bioinformatics* 2010, 26 (17), 2176–2182, doi : 10.1093/bioinformatics/btq401
- [16] Ø. Salvesen, J. Tatzelt , MA. Tranulis. The prion protein in neuroimmune crosstalk. *Neurochem Int*. 2019 Nov;130:104335. doi: 10.1016/j.neuint.2018.11.010.
- [17] S. Sakaguchi, J. Chida. Prion Protein is a Novel Modulator of Influenza: Potential Implications for Anti-Influenza Therapeutics. *Curr Issues Mol Biol*. 2020;37:21-32. doi: 10.21775/cimb.037.021.
- [18] G. Schmitt-Ulms, M. Mehrabian, D. Williams et al. The IDIP framework for assessing protein function and its application to the prion protein. *Biol Rev Camb Philos Soc*. 2021 May 6. doi: 10.1111/brv.12731
- [19] PB. Aldo, MJ. Mulla, R. Romero et al. Viral ssRNA induces first trimester trophoblast apoptosis through an inflammatory mechanism. *Am J Reprod Immunol*. 2010 Jul 1;64(1):27-37. doi: 10.1111/j.1600-0897.2010.00817.x.
- [20] G. Malachin, MR. Reiten, Ø. Salvesen et al. Loss of prion protein induces a primed state of type I interferon-responsive genes. *PLoS One*. 2017 Jun 26;12(6):e0179881. doi: 10.1371/journal.pone.0179881.

- [21] TJ. Kaitu'u-Lino, TM. MacDonald, P. Cannon et al. Circulating SPINT1 is a biomarker of pregnancies with poor placental function and fetal growth restriction. *Nat Commun.* 2020 May 15;11(1):2411. doi: 10.1038/s41467-020-16346-x.
- [22] W. Zhao, L. Cao, H. Ying et al. Endothelial CDS2 deficiency causes VEGFA-mediated vascular regression and tumor inhibition. *Cell Res.* 2019 Nov;29(11):895-910. doi: 10.1038/s41422-019-0229-5.
- [23] M. Wakamiya, MR. Blackburn, R. Jurecic et al. Disruption of the adenosine deaminase gene causes hepatocellular impairment and perinatal lethality in mice. *Proc Natl Acad Sci U S A.* 1995 Apr 25;92(9):3673-7. doi: 10.1073/pnas.92.9.3673.
- [24] MR. Blackburn, M. Wakamiya, CT. Caskey et al. Tissue-specific rescue suggests that placental adenosine deaminase is important for fetal development in mice. *J Biol Chem.* 1995 Oct 13;270(41):23891-4. doi: 10.1074/jbc.270.41.23891.
- [25] U. Werling, H. Schorle Transcription factor gene AP-2 gamma essential for early murine development. *Mol Cell Biol.* 2002 May;22(9):3149-56. doi: 10.1128/MCB.22.9.3149-3156.2002.
- [26] MC. Pérez-Aguilar, L. Goncalves, A. Ibarra et al., Adenosine deaminase as costimulatory molecule and marker of cellular immunity. *Invest Clin.* 2010 Dec;51(4):561-71.
- [27] Y. Yoneyama, R. Sawa, S. Suzuki et al. Relation between adenosine deaminase activities and cytokine-producing T cells in women with preeclampsia. *Clin Biochem.* 2002 Jun;35(4):303-6. doi: 10.1016/s0009-9120(02)00318-1.
- [28] R. Tang, C. Ma, J. Dong et al. Does adenosine deaminase play a key role in coronary artery disease. *Med Hypotheses.* 2006;67(2):371-4. doi: 10.1016/j.mehy.2006.01.038.
- [29] B. Kutryb-Zajac, P. Mierzejewska, EM. Slominska et al. Therapeutic Perspectives of Adenosine Deaminase Inhibition in Cardiovascular Diseases. *Molecules.* 2020 Oct 12;25(20):4652. doi: 10.3390/molecules25204652.
- [30] N. Alfaidy, S. Chauvet, S. Donadio-Andrei et al. Prion protein expression and functional importance in developmental angiogenesis: role in oxidative stress and copper homeostasis. *Antioxid Redox Signal.* 2013 Feb 1;18(4):400-11. doi: 10.1089/ars.2012.4637.

Hallmark gene set	WT vs POSO		WT vs POSOS-		WT vs POSOP-		WT vs POS-	
	Direction	FDR	Direction	FDR	Direction	FDR	Direction	FDR
Adipogenesis	Up	0,62552876	Up	0,80753343	Down	0,79673023	Up	0,79147888
Apoptosis	Down	0,93132096	Down	0,17156136	Down	0,16934382	Down	0,01640416
Cholesterol homeostasis	Up	0,90561461	Down	0,85373899	Down	0,49413621	Down	0,71885689
E2F targets	Down	0,90561461	Up	0,19319905	Up	0,31979891	Up	0,11180027
Epithelial mesenchymal transition	Down	0,93132096	Down	0,4305476	Down	0,31979891	Down	0,1308924
Hypoxia	Up	0,90561461	Down	0,42575279	Down	0,18867174	Down	0,11180027
<i>Inflammatory response</i>	Up	0,90561461	Down	0,10111071	Down	0,18867174	<i>Down</i>	<i>0,07054624</i>
Interferon alpha response	Down	0,90561461	Down	0,00193216	Down	0,00379274	Down	0,00041329
Interferon gamma response	Down	0,90561461	Down	0,00463537	Down	0,00972725	Down	0,00075138
Notch signaling	Down	0,90561461	Up	0,80753343	Up	0,82613941	Down	0,9957742
Reactive oxygen species pathway	Up	0,90561461	Down	0,01564074	Down	0,18867174	Down	0,17771965
TGF beta signaling	Up	0,90561461	Down	0,57494044	Down	0,557864	Down	0,79147888
Wnt beta catenin signaling	Down	0,90561461	Up	0,19319905	Up	0,18867174	Up	0,10479931
Xenobiotic metabolism	Up	0,62552876	Down	0,80753343	Down	0,68538223	Up	0,95587952

Table 1: Hallmark gene set analyses at E6.5.

Top margin : Compared genotypes. P0 : *Prnp*^{0/0}. SO : *Sprn*^{0/0}. S- : knockdown of *Sprn*. P- : knockdown of *Prnp*. For each knockdown, two independent lentiviral ShRNA vectors were used (see Material and Methods).

Left margin : hallmark gene sets [13,14].

Significantly altered hallmark gene sets are highlighted in boldface (FDR < 0.05) and italicized (FDR < 0.10).

Gene Name	Description	NCBI Gene	Log Fold Change	Adjusted P-Value	Embryo Ectoderm	Embryo Endoderm	Embryo Mesenchyme	Extraembryonic Component
Spint1	Serine protease inhibitor, Kunitz type 1	20732	1,599051	1,96414E-08	✓	✓	✓	✓
Gm30906	Long non-coding RNA	102632964	-1,477668	1,96414E-08	✓			
Scg5	Secretogranin V, secreted chaperone protein	20394	-1,334427	4,2595E-08	✓		✓	
Spg11	Spatacsin vesicle trafficking associated	214585	-1,081024	2,05026E-06	✓		✓	
Cds2	CDP-diacylglycerol synthase 2	110911	1,297156	2,42507E-06	✓		✓	✓
Jmjd7	Jumonji domain containing 7	433466	-1,479236	1,31005E-05	✓		✓	
Ada	Adenosine deaminase	11486	-2,117557	4,32324E-05	✓		✓	✓
AK148702		RIKEN clone 7120437D13	2,819679	0,004937838	---	---	---	---
Cplx2	Complexin 2	12890	2,616736	0,010457547	✓		✓	
Gm10734	-	RIKEN clone I530011G18	-1,104109	0,010457547	✓		✓	
Sdc4	Syndecan 4	20971	-1,157117	0,021156447	✓		✓	

Table 2: Differentially expressed genes between *Prnp*^{0/0}, *Sprn*^{0/0} and WT E6.5 mouse embryos.

Results are shown for significantly differentially expressed genes (FDR < 0.05, absolute log fold change ≥ 1). Checkmarks for each gene represent reported expression in embryo ectoderm, embryo endoderm, embryo mesenchyme, and extraembryonic component (<http://www.informatics.jax.org/expression.shtml>). Blank spaces and dashes represent unreported expression and no available data, respectively.